Clinical Trial Update: Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults [Phase 3]

View source ↗

Summary

A Phase 3 pivotal study evaluating safety and immunogenicity of a live-attenuated Chikungunya virus vaccine in adults has completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya Virus Infection

Drugs mentioned

• Valneva Chikungunya vaccine candidate (live-attenuated)

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2022-07-25